Silencing p110β prevents rapid depletion of nuclear pAkt

Biochemical and Biophysical Research Communications

Volumn 415, Issue 4, 2011, Pages 613-618

  Ye, Zhi wei ^a   Ghalali, Aram ^a   Högberg, Johan ^a   Stenius, Ulla ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Akt; ATP; P110 ; Statin

Indexed keywords

ADENOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110BETA; PURINERGIC P2X7 RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; EMBRYO; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR;

ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; FIBROBLASTS; GENE SILENCING; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MICE, KNOCKOUT; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRROLES; RNA, SMALL INTERFERING; TACROLIMUS BINDING PROTEINS;

MUS;

EID: 84855885805     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.10.120     Document Type: Article

References (26)

1. Hers I., Vincent E.E., Tavare J.M. Akt signalling in health and disease. Cell. Signal. 2011, 23:1515-1527.
2. Martelli A.M., Faenza I., Billi A.M., Manzoli L., Evangelisti C., Fala F., Cocco L. Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?. Cell. Signal. 2006, 18:1101-1107.
3. Mistafa O., Ghalali A., Kadekar S., Hogberg J., Stenius U. Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases. J. Biol. Chem. 2010, 285:27900-27910.
4. Mistafa O., Hogberg J., Stenius U. Statins and ATP regulate nuclear pAkt via the P2X7 purinergic receptor in epithelial cells. Biochem. Biophys. Res. Commun. 2008, 365:131-136.
5. Mistafa O., Stenius U. Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochem. Pharmacol. 2009, 78:1115-1126.
6. Trotman L.C., Wang X., Alimonti A., Chen Z., Teruya-Feldstein J., Yang H., Pavletich N.P., Carver B.S., Cordon-Cardo C., Erdjument-Bromage H., Tempst P., Chi S.G., Kim H.J., Misteli T., Jiang X., Pandolfi P.P. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007, 128:141-156.
7. Van de Sande T., Roskams T., Lerut E., Joniau S., Van Poppel H., Verhoeven G., Swinnen J.V. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J. Pathol. 2005, 206:214-219.
8. Roudier E., Mistafa O., Stenius U. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol. Cancer Ther. 2006, 5:2706-2715.
9. Ravenna L., Sale P., Di Vito M., Russo A., Salvatori L., Tafani M., Mari E., Sentinelli S., Petrangeli E., Gallucci M., Di Silverio F., Russo M.A. Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. Prostate 2009, 69:1245-1255.
10. Janssens R., Boeynaems J.M. Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. Br. J. Pharmacol. 2001, 132:536-546.
11. Shabbir M., Burnstock G. Purinergic receptor-mediated effects of adenosine 5'-triphosphate in urological malignant diseases. Int. J. Urol. 2009, 16:143-150.
12. Farwell W.R., D'Avolio L.W., Scranton R.E., Lawler E.V., Gaziano J.M. Statins and prostate cancer diagnosis and grade in a veterans population. J. Natl Cancer Inst. 2011, 103:885-892.
13. Hamilton R.J., Freedland S.J. Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr. Opin. Urol. 2008, 18:333-339.
14. Marques M., Kumar A., Poveda A.M., Zuluaga S., Hernandez C., Jackson S., Pasero P., Carrera A.C. Specific function of phosphoinositide 3-kinase beta in the control of DNA replication. Proc. Natl. Acad. Sci. USA 2009, 106:7525-7530.
15. Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S.H., Zhang J., Signoretti S., Loda M., Roberts T.M., Zhao J.J. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454:776-779.
16. Rabinovsky R., Pochanard P., McNear C., Brachmann S.M., Duke-Cohan J.S., Garraway L.A., Sellers W.R. p85 associates with unphosphorylated PTEN and the PTEN-associated complex. Mol. Cell. Biol. 2009, 29:5377-5388.
17. Vogt P.K. PI3K p110beta: more tightly controlled or constitutively active?. Mol. Cell 2011, 41:499-501.
18. Dbouk H.A., Backer J.M. A beta version of life: p110beta takes center stage. Oncotarget 2010, 1:729-733.
19. Lee S.H., Poulogiannis G., Pyne S., Jia S., Zou L., Signoretti S., Loda M., Cantley L.C., Roberts T.M. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc. Natl. Acad. Sci. USA 2010, 107:11002-11007.
20. Paajarvi G., Roudier E., Crisby M., Hogberg J., Stenius U. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J. 2005, 19:476-478.
21. Pei H., Li L., Fridley B.L., Jenkins G.D., Kalari K.R., Lingle W., Petersen G., Lou Z., Wang L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009, 16:259-266.
22. Dou Z., Chattopadhyay M., Pan J.A., Guerriero J.L., Jiang Y.P., Ballou L.M., Yue Z., Lin R.Z., Zong W.X. The class IA phosphatidylinositol 3-kinase p110-beta subunit is a positive regulator of autophagy. J. Cell Biol. 2010, 191:827-843.
23. Montironi R., Mazzuccheli R., Scarpelli M., Lopez-Beltran A., Fellegara G., Algaba F. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int. 2005, 95:1146-1152.
24. Kumar A., Redondo-Munoz J., Perez-Garcia V., Cortes I., Chagoyen M., Carrera A.C. Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival. Mol. Cell. Biol. 2011, 31:2122-2133.
25. Zhu Q., Youn H., Tang J., Tawfik O., Dennis K., Terranova P.F., Du J., Raynal P., Thrasher J.B., Li B. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 2008, 27:4569-4579.
26. E. Miraglia, J. Hogberg, U. Stenius, Statins exhibit anticancer effects through modifications of the pAkt signaling pathway, Int. J. Oncol. (2011) doi:10.3892/ijo.2011.1223.